225 related articles for article (PubMed ID: 30912163)
1. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
Brings A; Lehmann ML; Foerster KI; Burhenne J; Weiss J; Haefeli WE; Czock D
Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
Gouin-Thibault I; Delavenne X; Blanchard A; Siguret V; Salem JE; Narjoz C; Gaussem P; Beaune P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA
J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
[TBL] [Abstract][Full Text] [Related]
6. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
9. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
12. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.
Moore KT; Vaidyanathan S; Natarajan J; Ariyawansa J; Haskell L; Turner KC
J Clin Pharmacol; 2014 Dec; 54(12):1407-20. PubMed ID: 24964176
[TBL] [Abstract][Full Text] [Related]
13. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
14. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD
Br J Clin Pharmacol; 2019 Jul; 85(7):1464-1473. PubMed ID: 30845347
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
[TBL] [Abstract][Full Text] [Related]
18. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
[TBL] [Abstract][Full Text] [Related]
20. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
De Buck S; Kucher K; Hara H; Gray C; Woessner R
Biopharm Drug Dispos; 2018 Sep; 39(8):394-402. PubMed ID: 30171694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]